GLP 1 thyroid cancer warning covers two rare conditions as pills change levothyroxine timing

DALLAS. The GLP 1 thyroid cancer warning applies to two rare conditions, not to most thyroid disease, a UT Southwestern endocrinologist wrote on 28 October. Jeffrey Zigman said people with hypothyroidism, nodules or common thyroid cancers are not ruled out by that label language alone. His article, released by UT Southwestern Medical Center and republished by News-Medical, also sets out how people on levothyroxine might time the new daily GLP 1 pills. The piece is expert guidance. It reports no new trial data, and its timing advice is one clinician's routine rather than a tested protocol.

What the thyroid warning covers

The GLP 1 thyroid cancer warning tells people not to use these drugs if they or a family member have had medullary thyroid carcinoma, or if they have multiple endocrine neoplasia syndrome type 2, known as MEN2. Zigman, a professor of internal medicine in the endocrinology division, wrote that the wording often alarms people with any thyroid history. He drew a line between cell types. Medullary thyroid carcinoma arises in thyroid C cells. The more common thyroid cancers start in follicular cells, the cells that make thyroid hormone. According to the article, papillary, follicular and Hürthle cell cancers come from that different cell type. Zigman wrote that they do not carry the same concern with GLP 1 drugs, and neither do goiter, Graves' disease or Hashimoto's disease.

The caution traces back to animal work. Zigman wrote that some GLP 1 drugs drove growth and extra activity in the C cells of rodents, and that tumors eventually appeared in some of the animals. MEN2 is the second group named in the warning. It is an inherited cancer syndrome that stems from an altered RET gene, a gene involved in cell growth, C cells included. The article says roughly 95% of those with MEN2A, its most common form, test positive for medullary thyroid carcinoma. MEN2 can also raise the risk of adrenal gland tumors and of overactive parathyroid glands. Anyone who carries a known RET mutation, or whose own or family history includes MEN2, should avoid GLP 1 drugs, Zigman wrote.

Human data so far and its limits

Zigman wrote that human thyroid tissue may not react the way rodent tissue does, and that human studies so far have been reassuring. He pointed to a large Scandinavian study that found no substantial rise in thyroid cancer among people using GLP 1 receptor agonists, who were followed for close to four years on average. A Scandinavian cohort study by Björn Pasternak and colleagues on this question was published in The BMJ in April 2024. Zigman wrote that other large studies reached similar conclusions. Our desk has reported that the meaning of rodent thyroid tumor findings for people remains unsettled. The new article does not add data to that question. It explains why the label reads the way it does.

Because medullary thyroid carcinoma is rare, Zigman wrote, even studies of hundreds of thousands of patients may hold too few cases to rule out a long term risk.

The gap in the evidence is size. Because medullary thyroid carcinoma is rare, Zigman wrote, even studies of hundreds of thousands of patients may hold too few cases to rule out a long term risk. He said that uncertainty is why the Food and Drug Administration tells people at raised risk of that cancer not to use these weight management drugs. The GLP 1 thyroid cancer warning therefore reflects what studies cannot yet exclude, not a proven harm in humans. Zigman also wrote that people with no personal or family history of medullary thyroid carcinoma or MEN2 do not need RET gene testing before they start treatment. Anyone with another thyroid condition should still tell their doctor before starting, he added.

Levothyroxine timing with oral Wegovy and Foundayo

The second half of the article deals with daily routine. Levothyroxine is the most widely used hypothyroidism treatment, and its absorption can drop when food, supplements or certain drugs share the stomach with it. Zigman wrote that levothyroxine timing does not need to change for weekly GLP 1 injections, and people may swallow the thyroid pill alongside that morning routine if they wish. The pills differ. For the once daily Wegovy tablet, Zigman described a stricter routine: swallow it first thing after waking, before any food, with a small glass holding at most 4 ounces of water and nothing else taken alongside, then hold off for 30 minutes. Readers can see how the first GLP 1 pill gets a peptide through the gut.

Foundayo, the brand name for orforglipron, is the other daily pill named in the article. Zigman wrote that it can go down together with other medicines, but that neither oral Wegovy nor Foundayo should be swallowed at the same moment as levothyroxine. For people on oral Wegovy, his routine puts the GLP 1 tablet first on waking and levothyroxine after the wait, with breakfast at least 30 minutes later. For Foundayo users, levothyroxine comes first, breakfast follows after at least 30 minutes, and Foundayo is taken with the other morning medicines. Orforglipron acts on the GLP 1 receptor but is not a peptide at all, our desk has reported. Zigman described these steps as what he generally recommends and told readers to agree a schedule with their own doctor.

Weight change and open questions

Weight loss can change thyroid treatment too. Levothyroxine dosing depends partly on body weight, Zigman wrote, so a large change in weight can change how much a person needs. He said a gain or loss of 10 to 20 pounds is usually the point at which he asks patients to check in with their doctor, and symptoms can justify testing sooner. Signs of too little thyroid hormone can include constipation, fatigue, dry skin, low mood and feeling cold. Signs of too much can include anxiety, palpitations, shaky hands, sweating and poor sleep. He stressed that these symptoms have many causes, and that a blood test shows whether hormone levels are in range. He also put the weight tied to untreated hypothyroidism at roughly five to 10 pounds, mostly retained salt and water.

Several questions about the GLP 1 thyroid cancer warning and daily dosing routines remain open. The article does not cite a study that tested these pill schedules head to head, and it gives no data on how often levothyroxine needs adjusting during GLP 1 treatment. It does not report how many patients Zigman's clinic has treated this way. Long term human data on medullary thyroid carcinoma remain limited for the reason he gave: the cancer is rare. For people who cannot or prefer not to use a GLP 1 drug, Zigman listed other medicines, diet and exercise support, endobariatric procedures and bariatric surgery as options to discuss. Readers who want primary detail can read the UT Southwestern article in full. This report is research news, not medical advice.

Conclusion

The GLP 1 thyroid cancer warning covers people whose own or family history includes medullary thyroid carcinoma, plus people with MEN2, according to UT Southwestern's Jeffrey Zigman. Most other thyroid conditions do not rule out treatment on their own. The practical change is for people on levothyroxine who start a daily GLP 1 pill, where spacing doses matters. Zigman's routine is expert advice, not a trial result, so patients should set timing with their prescriber and keep up thyroid blood tests.